Vertex Pharmaceuticals Inc (VRTX) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Tr...
Vertex Pharmaceuticals Inc (VRTX) currently trades at a P/E ratio of 32.24 (historical range: 25.00–35.04, median: 29.63), placing it at the 74th percentile — above its historical average, P/S ratio of 11.45 (range: 8.32–12.55, 82th percentile — expensive relative to its history).
Vertex Pharmaceuticals Inc appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 32.24 | 25.00 | 29.63 | 35.04 | 74th | above its historical average |
| P/S Ratio | 11.45 | 8.32 | 10.31 | 12.55 | 82th | expensive relative to its history |
| FCF Yield | 0.01 | 0.01 | 0.01 | 0.03 | 19th | expensive relative to its history |